78 related articles for article (PubMed ID: 15530133)
1. Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period.
Rousseau A; Marquet P
Clin Pharmacokinet; 2004; 43(14):1055-7. PubMed ID: 15530133
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
[TBL] [Abstract][Full Text] [Related]
3. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.
Falck P; Midtvedt K; Vân Lê TT; Storehagen L; Holdaas H; Hartmann A; Asberg A
Clin Pharmacokinet; 2009; 48(9):615-23. PubMed ID: 19725595
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.
Lukas JC; Suárez AM; Valverde MP; Calvo MV; Lanao JM; Calvo R; Suarez E; Gil AD
J Clin Pharm Ther; 2005 Dec; 30(6):549-57. PubMed ID: 16336287
[TBL] [Abstract][Full Text] [Related]
5. Application of a gamma model of absorption to oral cyclosporin.
Debord J; Risco E; Harel M; Le Meur Y; Büchler M; Lachâtre G; Le Guellec C; Marquet P
Clin Pharmacokinet; 2001; 40(5):375-82. PubMed ID: 11432538
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
8. Ciclosporin kinetics in children after stem cell transplantation.
Willemze AJ; Cremers SC; Schoemaker RC; Lankester AC; den Hartigh J; Burggraaf J; Vossen JM
Br J Clin Pharmacol; 2008 Oct; 66(4):539-45. PubMed ID: 18492124
[TBL] [Abstract][Full Text] [Related]
9. Incorporating nonlinear kinetics to improve predictive performance of population pharmacokinetic models for ciclosporin in adult renal transplant recipients: A comparison of modelling strategies.
Mao J; Jiao Z; Qiu X; Zhang M; Zhong M
Eur J Pharm Sci; 2020 Oct; 153():105471. PubMed ID: 32682934
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
11. Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.
Mendonza AE; Gohh RY; Akhlaghi F
Clin Pharmacokinet; 2008; 47(11):733-42. PubMed ID: 18840028
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.
Woillard JB; Lebreton V; Neely M; Turlure P; Girault S; Debord J; Marquet P; Saint-Marcoux F
Br J Clin Pharmacol; 2014 Oct; 78(4):836-46. PubMed ID: 24698009
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
15. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.
Picard N; Prémaud A; Rousseau A; Le Meur Y; Marquet P
Br J Clin Pharmacol; 2006 Oct; 62(4):477-84. PubMed ID: 16995869
[TBL] [Abstract][Full Text] [Related]
18. Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.
Fanta S; Jönsson S; Backman JT; Karlsson MO; Hoppu K
Br J Clin Pharmacol; 2007 Dec; 64(6):772-84. PubMed ID: 17662086
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.
Zhao W; Fakhoury M; Deschênes G; Roussey G; Brochard K; Niaudet P; Tsimaratos M; André JL; Cloarec S; Cochat P; Bensman A; Azougagh S; Jacqz-Aigrain E
J Clin Pharmacol; 2010 Nov; 50(11):1280-91. PubMed ID: 20147615
[TBL] [Abstract][Full Text] [Related]
20. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
Musuamba FT; Mourad M; Haufroid V; Demeyer M; Capron A; Delattre IK; Delaruelle F; Wallemacq P; Verbeeck RK
J Clin Pharmacol; 2012 Dec; 52(12):1833-43. PubMed ID: 22207766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
